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RESEARCH ARTICLE
Association between Computed
Tomographic Biomarkers of Cerebral
Small Vessel Diseases and Long-Term
Outcome after Spontaneous Intracerebral
Hemorrhage
Mark A. Rodrigues, FRCR, PhD ,1,2 Neshika E. Samarasekera, MRCP, PhD ,1
Christine Lerpiniere, RGN,1 Luke A. Perry, MBBS,3 Tom J. Moullaali, MBBS, MRCP ,1
James J.M. Loan, MRCS, MSc ,1,4,5 Joanna M. Wardlaw, FRCR, MD ,1,6,7 and
Rustam Al-Shahi Salman, MA PhD FRCPEdin FESO, 1
for the Lothian Audit of the Treatment of Cerebral Haemorrhage Collaborators†
Objective: A study was undertaken to assess whether cerebral small vessel disease (SVD) computed tomographic
(CT) biomarkers are associated with long-term outcome after intracerebral hemorrhage.
Methods: We performed a prospective, community-based cohort study of adults diagnosed with spontaneous
intracerebral hemorrhage between June 1, 2010 and May 31, 2013. A neuroradiologist rated the diagnostic brain
CT for acute intracerebral hemorrhage features and SVD biomarkers. We used severity of white matter lucencies
and cerebral atrophy, and the number of lacunes to calculate the CT SVD score. We assessed the association
between CT SVD biomarkers and either death, or death or dependence (modified Rankin Scale scores = 4–6)
1 year after first-ever intracerebral hemorrhage using logistic regression, adjusting for known predictors of
outcome.
Results: Within 1 year of intracerebral hemorrhage, 224 (56%) of 402 patients died. In separate models, 1-year
death was associated with severe atrophy (adjusted odds ratio [aOR] = 2.54, 95% confidence interval [CI] = 1.44–
4.49, p = 0.001) but not lacunes or severe white matter lucencies, and CT SVD sum score ≥ 1 (aOR = 2.50, 95%
CI = 1.40–4.45, p = 0.002). Two hundred seventy-seven (73%) of 378 patients with modified Rankin Scale data
were dead or dependent at 1 year. In separate models, 1-year death or dependence was associated with severe
atrophy (aOR = 3.67, 95% CI = 1.71–7.89, p = 0.001) and severe white matter lucencies (aOR = 2.18, 95%
CI = 1.06–4.51, p = 0.035) but not lacunes, and CT SVD sum score ≥ 1 (aOR = 2.81, 95% CI = 1.45–5.46,
p = 0.002).
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Interpretation: SVD biomarkers on the diagnostic brain CT are associated with 1-year death and dependence after
intracerebral hemorrhage, independent of known predictors of outcome.
ANN NEUROL 2020;00:1–14
Spontaneous intracerebral hemorrhage (ICH) accountsfor 9 to 27% of strokes worldwide and is the most severe
type of stroke.1 One-month and 1-year case fatalities are
around 40 and 55%, respectively.1,2 Survivors of ICH attrib-
uted to cerebral small vessel diseases (SVDs) are often left dis-
abled, with 16 to 46% functionally dependent on others at
6 months, and 43 to 46% are dependent at 1 year.3
Determining risk factors for poor outcome after
ICH is important to inform discussions about prognosis
with patients and their carers, and to guide treatment
decisions. Well-established risk factors for poor outcome
after ICH include increasing age, decreasing conscious
level on admission, and features of ICH, such as location,
increasing volume, and the presence of intraventricular
hemorrhage.3,4 Most of these risk factors represent the
severity and consequences of ICH, but outcome may also
be determined by the brain in which ICH occurs.
We hypothesized that the severity of SVD on brain
imaging may be a risk factor for death or dependence after
ICH. About 85% of ICHs are attributed to SVDs, which
usually underlie such ICHs.5,6 SVDs may have many sub-
sequent manifestations other than recurrent ICH, such as
dementia7,8 and ischemic stroke.9 Furthermore, SVD bio-
markers are associated with physical disabilities in elderly
patients without ICH10 and poor 90-day and 6-month
functional outcome after ischemic stroke.11,12
White matter lucencies (WMLs) on brain computed
tomography (CT) were associated with poor 28- and 90-day
functional outcome and 90-day death after SVD-ICH in a
recent meta-analysis of 9 studies, whichmay have been affected
by selection bias.13 Less is known about the association of not
only WMLs but also other individual CT SVD biomarkers
(such as lacunes and cerebral atrophy14–16) with longer-term
outcomes after SVD-ICH. Composite SVD-burden scores
have shown added prognostic value over individual SVD bio-
markers in other settings11,17–21; however, the association of
the CT SVD score22 with SVD-ICH outcome is unknown.
We aimed to assess the associations of SVD bio-
markers on the first brain CT to diagnose spontaneous
ICH—individually and as a composite CT SVD score—
with 1-year death or dependence after first-ever SVD-ICH
in a prospective, community-based cohort study.
Patients and Methods
Study Design, Setting, and Patients
We performed a community-based inception cohort study
of patients with spontaneous ICH living in the Lothian
health board region of Scotland (Lothian Audit of the
Treatment of Cerebral Hemorrhage [LATCH]).5 We pro-
spectively identified all incident cases of spontaneous ICH
in adults (aged ≥16 years) between June 1, 2010 and May
31, 2013 inclusive using multiple overlapping sources of
case ascertainment.5 For this study, we excluded patients
with ICH secondary to an underlying macrovascular or
structural cause other than SVDs, patients with a previous
symptomatic ICH, and patients without a diagnostic non-
contrast brain CT.
The NHS Lothian Caldicott Guardian approved
LATCH (reference number 1501). Patients in NHS Lot-
hian were informed about the use of their data for audit,
and information leaflets about LATCH were distributed
to inform patients and their carers about their right to opt
out. Analysis of an anonymized dataset did not require
research ethics committee approval.
Risk Factors
We collected demographics and the presence of relevant
comorbidities, baseline clinical data, and medication use at
the time of ICH by interviewing patients and their fami-
lies at the time of presentation and reviewing primary and
secondary care records.5
One neuroradiologist (M.A.R.) reformatted the diag-
nostic noncontrast brain CT into standard axial, coronal,
and sagittal planes and used a standardized pro forma
derived from large-scale stroke studies to assess the images
as previously described.6 M.A.R. evaluated the number
and location of acute ICHs,23 the ICH volume using an
ABC/2 approach,24 and the presence of extra-axial hemor-
rhage (in subarachnoid, subdural, or intraventricular
spaces). M.A.R. graded anterior and posterior WMLs sep-
arately as absent (0), lucency restricted to the per-
iventricular white matter (1), or lucency covering the
entire region from the lateral ventricle to the cortex
(2) using the van Swieten scale.25 M.A.R. separately rated
cortical and central atrophy as none (0), moderate (1), or
severe (2) against a standard template.11 M.A.R. assessed
WMLs and atrophy in the cerebral hemisphere contralat-
eral to the ICH to reduce the effect of perihematomal
edema and local mass effect. M.A.R. counted the number
of lacunes, defined as a round or ovoid subcortical
hypoattenuating lesion between 3 and 15mm in diameter
in the territory of 1 perforating arteriole.26 MAR per-
formed the CT reformatting and ratings using Carestream
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Vue PACS (v11.3.2; Carestream Health, Rochester, NY),
masked to clinical and outcome information.
We calculated the CT SVD sum score22 by
awarding 1 point for each of the following: (1) severe (=2)
WMLs in the anterior or posterior periventricular white
matter, (2) ≥2 lacunes, and (3) severe (=2) central or corti-
cal atrophy. The ordinal sum score quantifies the global
burden of SVD (Fig 1) from 0 (no imaging features of
severe SVD) to 3 (all 3 severe imaging features of SVD).
Outcomes
We used multiple sources of information to follow up
patients, including annual primary care practitioner postal
questionnaires, yearly review of NHS Lothian’s secondary
care electronic records system, and evaluation of primary
care records for all patients who died.5
We assessed outcome 1 year after ICH to allow
functional recovery from the consequences of acute ICH
during the first year afterward.3,27 We prespecified 2 out-
comes: (1) death from any cause; and (2) death or depen-
dence, which we defined—as others have done, in view of
the spectrum of severity of outcome after ICH28–31—as a
modified Rankin Scale score of 4 to 6.32
A consultant vascular neurologist (R.A.-S.S.) con-
firmed the cause and date of death using the death certifi-
cate and primary care and hospital records, masked to the
CT ratings. The 1-year modified Rankin Scale score was
ascertained in surviving patients with a postal question-
naire sent to the patients’ primary care practitioners. The
primary care practitioners used all available clinical infor-
mation to derive the modified Rankin Scale score,
unaware of this study of CT ratings of SVD.
Sample Size
We used the largest sample size possible from a 3-year
community-based cohort study to maximize power and
generalizability. We reduced overfitting by prespecifying
risk factors and building multivariable models with at least
10 outcome events per risk factor.33
Missing Data
We excluded patients with missing risk factors or out-
comes from the relevant analyses due to the infrequency
of missing data.
Statistical Analysis
For the 2 outcomes, death and death or dependence at
1 year after ICH, we compared the frequency of clinical
characteristics and diagnostic noncontrast brain CT fea-
tures between groups using the χ2 test for categorical vari-
ables and the Mann–Whitney U test for non-normally
distributed continuous variables. We corrected for
multiple comparisons for each outcome using the Ben-
jamini and Hochberg method.34
We performed multivariable logistic regression to
assess whether CT SVD biomarkers were associated with
FIGURE 1: Example axial noncontrast brain computed
tomographic (CT) images at the level of the lateral
ventricular choroid plexus (A, C, E, and G) and centrum
semiovale (B, D, F, and H) showing the range of CT small
vessel disease (SVD) scores in patients with first-ever SVD–
intracerebral hemorrhage (ICH). (A, B) CT SVD score
0 (anterior white matter lucencies [WMLs] = 0, posterior
WMLs = 0, no lacunes, central atrophy = 0, cortical
atrophy = 0). (C, D) CT SVD 1 (anterior WMLs = 1, posterior
WMLs = 1, no lacunes, central atrophy = 1, cortical
atrophy = 2). (E, F) CT SVD 2 (anterior WMLs = 2, posterior
WMLs = 2, no lacunes, central atrophy = 2, cortical
atrophy = 2). (G, H) CT SVD 3 (anterior WMLs = 2, posterior
WMLs = 2, 4 lacunes [one of which is visible in the left corona
radiata], central atrophy = 2, cortical atrophy = 1).
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each outcome independent of prespecified predictors. We
included 10 prespecified predictors (age, sex, pre-ICH
diagnosis of dementia, pre-ICH diagnosis of diabetes, anti-
platelet and anticoagulant use at the time of the ICH,
admission Glasgow Coma Scale [GCS] score, location of
the largest ICH [lobar vs nonlobar (deep and
infratentorial)], volume of the largest ICH, and intraven-
tricular hemorrhage) based on the variables most fre-
quently associated with long-term survival and functional
outcome after ICH.3,35 In the first model (separate CT
SVD biomarkers model), we also included the 3 compo-
nents of the CT SVD score (severe anterior or posterior
WMLs, severe cortical or central atrophy, and ≥2 lacunes)
as separate covariates. In the second model (CT SVD sum
score model), we included the composite CT SVD score
alone, dichotomized (0 vs ≥1) to differentiate patients
with (CT SVD score ≥ 1) and without (CT SVD score = 0)
evidence of severe SVD on CT. We modeled the continu-
ous predictors age, GCS score on admission, and ICH
volume as linear associations, as there was no evidence of
nonlinearity. We did not include any interaction terms, as
there was no evidence of any interaction between ICH
location, ICH volume, and CT SVD score.
We compared the multivariable logistic regression
models against the ICH score4 for the 2 outcomes using
the c statistic and DeLong’s test for 2 correlated receiver
operating characteristic curves.
The use of do not attempt resuscitation orders, with-
drawal of active care, and the provision of rehabilitation,
which are associated with death and functional outcome
after ICH,36–39 may have been influenced by some of the
predictors included in the models. Therefore, we per-
formed post hoc sensitivity analyses in patients who sur-
vived at least 30 days after their first-ever ICH. Patients
with a pre-ICH modified Rankin Scale score of 4 or 5 are
unlikely to improve their function after ICH. Therefore,
we performed post hoc sensitivity analyses in patients with
a pre-ICH modified Rankin Scale score of 0 to 3.
We performed the statistical analyses using R statisti-
cal package version 3.4.4.
Results
Between June 1, 2010 and May 31, 2013, there were
530 patients with incident spontaneous ICH, 418 of whom
had a first-ever SVD-ICH. We included 402 (96%) with
baseline diagnostic noncontrast brain CT and complete base-
line data (Fig 2). The median age was 78 years (interquartile
range [IQR] = 68–84), and 185 were men (46%). The
median time between ICH onset and CT was 0 days
(IQR = 0–1). One hundred ninety-nine had a lobar ICH,
152 a deep ICH, and 51 an infratentorial ICH. The median
ICH volume was 20ml (IQR = 6–55), and 188 (47%) had
intraventricular hemorrhage.
One-Year Death after First-Ever SVD-ICH
Two hundred twenty-four patients (56%) were dead at 1 year
after their first-ever ICH, whereas 178 patients were alive.
FIGURE 2: Flow of patients. CT = computed tomography;
ICH = intracerebral hemorrhage; MRI = magnetic resonance
imaging; SVD = small vessel disease.
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Patients who died were older, with a more frequent history of
pre-ICH ischemic stroke, and had higher pre-ICH modified
Rankin Scale scores and lower GCS scores on admission on
univariate analysis (Table 1). Larger ICH volume and the
presence of intraventricular hemorrhage and subarachnoid
hemorrhage were also associated with death at 1 year, as were
increasing severity of WMLs and atrophy and more severe
CT SVD score (Table 2).
In the prespecified multivariable separate CT SVD
biomarkers model (Table 3), the presence of severe
TABLE 1. Baseline Clinical Features in First-Ever SVD-ICH Patients Who Were Alive at 1 Year after First-Ever ICH
versus Those Who Were Dead
Feature Alive at 1 Year, n = 178 Dead at 1 Year, n = 224 pa
Age, yr 74 (61–82) 79 (72–84) <0.001
Sex
Female 100 (56) 117 (52) 0.530
Male 78 (44) 107 (48)
Comorbidities
Hypertension 112 (63) 153 (68) 0.371
Ischemic stroke 20 (11) 48 (21) 0.015
Transient ischemic attack 16 (9) 29 (13) 0.322
Dementia 16 (9) 36 (16) 0.063
Diabetes 16 (9) 30 (13) 0.269
Atrial fibrillation 39 (22) 50 (22) 0.951
Myocardial infarction 11 (6) 26 (12) 0.104
Hyperlipidemia 28 (16) 43 (19) 0.487
Smoking statusb
Current 37 (21) 51 (23) 0.488
Ex-smoker 59 (33) 84 (38)
Never 82 (46) 87 (39)
Pre-ICH modified Rankin Scalec
0 81 (46) 48 (22)
1 37 (21) 46 (21)
2 30 (17) 58 (26)
3 25 (14) 55 (25)
4 5 (3) 10 (5)
5 0 (0) 3 (1)
Pre-ICH modified Rankin Scale 2 (1–3) 3 (2–4) <0.001
Medications on admission
Antiplatelet drug(s) 72 (40) 103 (46) 0.371
Anticoagulant drug(s) 22 (12) 32 (14) 0.656
Antihypertensive drug(s) 86 (48) 111 (50) 0.859
Admission GCS score 14 (14–15) 11 (6–14) <0.001
Data are n (%) or median (interquartile range).
aAdjusted for multiple comparisons using the Benjamini and Hochberg method.
bData missing in 2 patients.
cData missing in 4 patients.
GCS = Glasgow coma scale; ICH = intracerebral hemorrhage; SVD = small vessel disease.
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TABLE 2. Diagnostic Noncontrast Brain CT Features in First-Ever SVD-ICH Patients Who Were Alive at 1 Year
after First-Ever ICH versus Those Who Were Dead
Feature Alive at 1 Year, n = 178 Dead at 1 Year, n = 224 pa
ICH location
Lobar 91 (51) 108 (48) 0.650
Deep 68 (38) 84 (38)
Infratentorial 19 (11) 32 (14)
ICH volume, ml 10 (3–22) 38 (13–82) <0.001
Intraventricular hemorrhage 48 (27) 140 (63) <0.001
Subarachnoid hemorrhage 65 (37) 112 (50) 0.015
Subdural hemorrhage 12 (7) 30 (13) 0.057
Fingerlike projections 11 (6) 33 (15) 0.015
Number of lacunes 0 (0–1) 0 (0–1) 0.726
≥2 lacunes 33 (19) 41 (18) 0.952
Anterior WMLs
0 42 (24) 37 (17) 0.003
1 99 (56) 103 (46)
2 37 (21) 84 (38)
Posterior WMLs
0 71 (40) 53 (24) 0.003
1 41 (23) 52 (23)
2 66 (37) 119 (53)
Severe (=2) anterior or posterior WMLs 69 (39) 128 (57) 0.001
Central atrophy
0 56 (32) 45 (20) <0.001
1 109 (61) 131 (59)
2 13 (7) 48 (21)
Cortical atrophy
0 51 (29) 54 (24) 0.057
1 99 (56) 110 (49)
2 28 (16) 60 (27)
Severe (=2) central or cortical atrophy 37 (21) 91 (41) <0.001
CT SVD score
0 82 (46) 54 (24) <0.001
1 60 (34) 94 (42)
2 29 (16) 62 (28)
3 7 (4) 14 (6)
CT SVD score ≥ 1 96 (54) 170 (76) <0.001
Data are n (%) or median (interquartile range). ICH location and volume relate to the largest ICH if there were multiple acute ICHs on the diagnostic
brain CT.
aAdjusted for multiple comparisons using the Benjamini and Hochberg method.
CT = computed tomography; ICH = intracerebral hemorrhage; SVD = small vessel disease; WML = white matter lucency.
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atrophy was independently associated with death at 1 year
after adjusting for known predictors of long-term survival
in ICH (adjusted odds ratio [aOR] = 2.54, 95% confi-
dence interval [CI] = 1.44–4.49, p = 0.001). Severe
WMLs showed a borderline significant independent
association (aOR = 1.75, 95% CI = 0.99–3.08,
p = 0.053), whereas there was no significant association
between the presence of at least 2 lacunes and death. In
the prespecified multivariable CT SVD sum score model
(see Table 3), CT SVD score ≥ 1 was independently
TABLE 3. Multivariable Models for Death at 1 Year after First-Ever ICH in First-Ever SVD-ICH
β Coefficient (standard error) Odds Ratio (95% CI) p
Separate CT SVD biomarkers model
Intercept −2.64 (1.21)
Age, per year increase 0.04 (0.01) 1.05 (1.02–1.07) <0.001
Male sex 0.70 (0.28) 2.02 (1.17–3.49) 0.011
Pre-ICH dementia −0.16 (0.41 0.85 (0.38–1.92) 0.703
Pre-ICH diabetes 0.58 (0.42) 1.79 (0.78–4.10) 0.168
Antiplatelet use at ICH −0.54 (0.31) 0.59 (0.32–1.07) 0.080
Anticoagulant use at ICH −0.14 (0.42) 0.87 (0.38–1.97) 0.739
Admission GCS score, per point increase −0.21 (0.05) 0.81 (0.74–0.89) <0.001
Nonlobar ICH location 0.68 (0.30) 1.97 (1.10–3.55) 0.023
ICH volume, per ml increase 0.03 (0.01) 1.03 (1.02–1.04) <0.001
Intraventricular hemorrhage 0.63 (0.29) 1.88 (1.06–3.31) 0.030
≥2 lacunes −0.04 (0.34) 0.96 (0.50–1.86) 0.913
Severe anterior or posterior WMLs 0.56 (0.29) 1.75 (0.99–3.08) 0.053
Severe central or cortical atrophy 0.93 (0.29) 2.54 (1.44–4.49) 0.001
CT SVD sum score model
Intercept −3.07 (1.21)
Age, per year increase 0.05 (0.01) 1.05 (1.03–1.08) <0.001
Male sex 0.71 (0.27) 2.03 (1.19–3.47) 0.010
Pre-ICH dementia −0.13 (0.41) 0.87 (0.39–1.96) 0.746
Pre-ICH diabetes 0.44 (0.42) 1.55 (0.69–3.49) 0.294
Antiplatelet use at ICH −0.48 (0.30) 0.62 (0.35–1.12) 0.111
Anticoagulant use at ICH −0.09 (0.42) 0.91 (0.40–2.08) 0.827
Admission GCS score, per point increase −0.21 (0.05) 0.81 (0.73–0.89) <0.001
Nonlobar ICH location 0.67 (0.30) 1.95 (1.09–3.47) 0.024
ICH volume, per ml increase 0.03 (0.01) 1.03 (1.02–1.04) <0.001
Intraventricular hemorrhage 0.63 (0.29) 1.87 (1.06–3.29) 0.030
CT SVD score ≥ 1 0.92 (0.30) 2.50 (1.40–4.45) 0.002
ICH location and volume relate to the largest ICH if there were multiple acute ICHs on the diagnostic brain CT. CI = confidence interval;
CT = computed tomography; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; SVD = small vessel disease; WML = white matter
lucency.
7
Rodrigues et al: CT SVD Biomarkers in ICH
TABLE 4. Baseline Clinical Features in First-Ever SVD-ICH Patients Who Were Dead or Dependent (Modified
Rankin Scale = 4–6) at 1 Year after First-Ever ICH versus Those Who Were Not (Modified Rankin Scale = 0–3)
Feature Modified Rankin Scale = 0–3, n = 101 Modified Rankin Scale = 4–6, n = 277 pa
Age, yr 72 (60–81) 79 (71–84) <0.001
Sex
Female 55 (54) 150 (54) 0.989
Male 46 (46) 127 (46)
Comorbidities
Hypertension 60 (59) 189 (68) 0.184
Ischemic stroke 9 (9) 57 (21) 0.017
Transient ischemic attack 11 (11) 33 (12) 0.865
Dementia 7 (7) 43 (16) 0.052
Diabetes 5 (5) 38 (14) 0.035
Atrial fibrillation 21 (21) 63 (23) 0.831
Myocardial infarction 7 (7) 30 (11) 0.406
Hyperlipidemia 15 (15) 51 (18) 0.584
Smoking statusb
Current 23 (23) 59 (22) 0.883
Ex-smoker 34 (34) 102 (37)
Never 44 (44) 114 (42)
Pre-ICH modified Rankin Scalec
0 53 (53) 64 (23)
1 22 (22) 59 (22)
2 15 (15) 70 (26)
3 11 (11) 63 (23)
4 0 (0) 14 (5)
5 0 (0) 3 (1)
Pre-ICH modified Rankin Scale 1 (1–3) 3 (2–4) <0.001
Medications on admission
Antiplatelet drug(s) 40 (40) 127 (46) 0.406
Anticoagulant drug(s) 12 (12) 37 (13) 0.831
Antihypertensive drug(s) 49 (49) 140 (51) 0.831
Admission GCS score 15 (14–15) 12 (8–14) <0.001
Data are n (%) or median (interquartile range).
aAdjusted for multiple comparisons using the Benjamini and Hochberg method.
bData missing in 2 patients.
cData missing in 4 patients.
GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; SVD = small vessel disease.
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TABLE 5. Diagnostic Noncontrast Brain CT Features in First-Ever SVD-ICH Patients Who Were Dead or
Dependent (Modified Rankin Scale = 4–6) at 1 Year after First-Ever ICH versus Those Who Were Not (Modified
Rankin Scale = 0–3)
Feature Modified Rankin Scale = 0–3, n = 101 Modified Rankin Scale = 4–6, n = 277 pa
ICH location
Lobar 50 (49) 137 (49) 0.999
Deep 38 (38) 104 (38)
Infratentorial 13 (13) 36 (13)
ICH volume, ml 7 (3–16) 33 (12–77) <0.001
Intraventricular hemorrhage 19 (19) 167 (60) <0.001
Subarachnoid hemorrhage 35 (35) 133 (48) 0.039
Subdural hemorrhage 8 (8) 32 (12) 0.406
Fingerlike projections 4 (4) 39 (14) 0.015
Number of lacunes 0 (0–1) 0 (0–1) 0.808
≥2 lacunes 16 (16) 50 (18) 0.808
Anterior WMLs
0 31 (31) 44 (16) 0.002
1 51 (51) 135 (49)
2 19 (19) 98 (35)
Posterior WMLs
0 51 (51) 68 (25) <0.001
1 17 (17) 67 (24)
2 33 (33) 142 (51)
Severe (=2) anterior or posterior WMLs 34 (34) 152 (55) 0.001
Central atrophy
0 35 (35) 61 (22) <0.001
1 63 (62) 162 (59)
2 3 (3) 54 (19)
Cortical atrophy
0 26 (26) 70 (25) 0.017
1 64 (63) 137 (50)
2 11 (11) 70 (25)
Severe (=2) central or cortical atrophy 14 (14) 105 (38) <0.001
CT SVD score
0 54 (54) 75 (27) <0.001
1 33 (33) 113 (41)
2 11 (11) 73 (26)
3 3 (3) 16 (6)
CT SVD score ≥ 1 47 (47) 202 (73) <0.001
Data are n (%) or median (interquartile range). ICH location and volume relate to the largest ICH if there were multiple acute ICHs on the diagnostic
brain CT.
a Adjusted for multiple comparisons using the Benjamini and Hochberg method. CT = computed tomography.
ICH = intracerebral hemorrhage; SVD = small vessel disease; WML = white matter lucency.
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associated with death at 1 year after adjusting for known
predictors of long-term survival in ICH (aOR = 2.50,
95% CI = 1.40–4.45, p = 0.002). Increasing age, male
sex, decreasing admission GCS score, nonlobar ICH loca-
tion, increasing ICH volume, and the presence of
intraventricular hemorrhage were independently associated
with death at 1 year in both models.
The ICH score had a c statistic of 0.79 (95%
CI = 0.75–0.83) for 1-year death. The c statistic of both
the separate CT SVD biomarkers (0.86, 95% CI = 0.83–
TABLE 6. Multivariable Models for Death or Dependence (Modified Rankin Scale = 4–6) at 1 Year after First-
Ever ICH in First-Ever SVD-ICH
β Coefficient (standard error) Odds Ratio (95% CI) p
Separate CT SVD biomarkers model
Intercept −2.55 (1.74)
Age, per year increase 0.06 (0.02) 1.06 (1.02–1.09) 0.001
Male sex 0.42 (0.36) 1.53 (0.76–3.07) 0.233
Pre-ICH dementia −0.38 (0.57) 0.68 (0.22–2.08) 0.502
Pre-ICH diabetes 1.69 (0.60) 5.44 (1.67–17.71) 0.005
Antiplatelet use at ICH −0.78 (0.37) 0.46 (0.22–0.95) 0.036
Anticoagulant use at ICH −0.39 (0.53) 0.68 (0.24–1.90) 0.460
Admission GCS, per point increase −0.24 (0.08) 0.79 (0.68–0.92) 0.002
Nonlobar ICH location 0.64 (0.35) 1.90 (0.96–3.77) 0.066
ICH volume, per ml increase 0.05 (0.01) 1.05 (1.03–1.07) <0.001
Intraventricular hemorrhage 1.14 (0.38) 3.12 (1.48–6.58) 0.003
≥2 lacunes 0.02 (0.44) 1.02 (0.43–2.38) 0.972
Severe anterior or posterior WMLs 0.78 (0.37) 2.18 (1.06–4.51) 0.035
Severe central or cortical atrophy 1.30 (0.39) 3.67 (1.71–7.89) 0.001
CT SVD sum score model
Intercept −2.94 (1.71)
Age, per year increase 0.06 (0.02) 1.07 (1.03–1.10) <0.001
Male sex 0.47 (0.34) 1.59 (0.82–3.10) 0.170
Pre-ICH dementia −0.17 (0.55) 0.84 (0.29–2.44) 0.749
Pre-ICH diabetes 1.45 (0.59) 4.25 (1.33–13.59) 0.015
Antiplatelet use at ICH −0.66 (0.36) 0.52 (0.26–1.04) 0.064
Anticoagulant use at ICH −0.22 (0.52) 0.80 (0.29–2.21) 0.670
Admission GCS score, per point increase −0.25 (0.08) 0.78 (0.67–0.90) 0.001
Nonlobar ICH location 0.62 (0.34) 1.86 (0.95–3.65) 0.069
ICH volume, per ml increase 0.05 (0.01) 1.05 (1.03–1.07) <0.001
Intraventricular hemorrhage 1.11 (0.38) 3.02 (1.44–6.33) 0.003
CT SVD score ≥ 1 1.03 (0.34) 2.81 (1.45–5.46) 0.002
ICH location and volume relate to the largest ICH if there were multiple acute ICHs on the diagnostic brain CT. CI = confidence interval;
CT = computed tomography; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; SVD = small vessel disease; WML = white matter
lucency.
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0.90, p = 0.010) and the CT SVD sum (0.86, 95%
CI = 0.82–0.89, p = 0.013) multivariable models was sig-
nificantly higher than the ICH score.
In sensitivity analyses of 235 patients who survived
at least 30 days after their first-ever ICH, severe atrophy
(aOR = 2.24, 95% CI = 1.08–4.65, p = 0.030), and CT
SVD score ≥ 1 (aOR = 2.47, 95% CI = 1.16–5.29,
p = 0.020) remained independently associated with death
at 1 year in separate multivariable models.
One-Year Death or Dependence (Modified
Rankin Scale Scores 4–6) after First-Ever
SVD-ICH
Three hundred seventy-eight patients (94%) had complete
modified Rankin Scale data at 1 year (see Fig 2). Patients
with missing modified Rankin Scale outcome data had
higher admission GCS, smaller ICH volumes, and less fre-
quent intraventricular hemorrhage compared to those with
complete modified Rankin Scale outcome data. The base-
line clinical characteristics and diagnostic brain CT fea-
tures were otherwise similar between the 2 groups.
The median modified Rankin Scale score 1 year after
the index ICH was 2 (IQR = 1–3). One hundred one
patients (26.7%) were alive and independent (modified
Rankin Scale score = 0–3), and 277 patients (73.3%) were
dead or dependent (modified Rankin Scale score = 4–6).
Patients who were dead or dependent were older, and
more frequently had a history of pre-ICH ischemic stroke
or diabetes, worse pre-ICH modified Rankin Scale scores,
and lower GCS score on admission on univariate analysis
(Table 4). Larger ICH volume and the presence of intra-
ventricular hemorrhage and subarachnoid hemorrhage
were also associated with death or dependence at 1 year,
as were increasing severity of WMLs and atrophy and
more severe CT SVD score (Table 5).
In the prespecified multivariable separate CT SVD
biomarkers model, severe atrophy (aOR = 3.67, 95%
CI = 1.71–7.89, p = 0.001) and severe WMLs
(aOR = 2.18, 95% CI = 1.06–4.51, p = 0.035) were inde-
pendently associated with death or dependence at 1 year
after adjusting for known predictors of long-term func-
tional outcome after ICH (Table 6). There was no signifi-
cant association between the presence of at least 2 lacunes
and death or dependence. In the prespecified multivariable
CT SVD sum score model (see Table 6), CT SVD score
≥ 1 was independently associated with death or depen-
dence at 1 year after adjusting for known predictors of
long-term survival in ICH (aOR = 2.81, 95% CI = 1.45–
5.46, p = 0.002). Increasing age, pre-ICH history of dia-
betes, decreasing admission GCS score, increasing ICH
volume, and the presence of intraventricular hemorrhage
were independently associated with death or dependence
at 1 year in both models.
The ICH score had a c statistic of 0.82 (95%
CI = 0.76–0.86) for 1-year death or dependence. The c
statistic of both the separate CT SVD biomarkers (0.91,
95% CI = 0.88–0.94, p = 0.001) and the CT SVD sum
(0.90, 95% CI = 0.87–0.93, p = 0.002) multivariable
models was significantly higher than the ICH score.
In a sensitivity analysis of 211 patients who survived
at least 30 days after their first-ever ICH, severe atrophy
(aOR = 2.85, 95% CI = 1.26–6.48, p = 0.012) and CT
SVD score ≥ 1 (aOR = 2.33, 95% CI = 1.16–4.68,
p = 0.018) remained independently associated with 1-year
death or dependence. Severe WMLs approached but did
not achieve a statistically significant association
(aOR = 1.95, 95% CI = 0.90–4.20, p = 0.089).
Sensitivity analyses of 357 patients with a pre-ICH
modified Rankin Scale score of 0 to 3 showed similar sig-
nificance, direction, and magnitude of the independent
associations with 1-year death or dependence, suggesting
that pre-ICH dependence on others did not affect the
principal associations with outcome.
In post hoc sensitivity analyses trichotomizing ICH
location (lobar [reference], deep or infratentorial) in the multi-
variable models, deep ICH location remained statistically sig-
nificantly associated with 1-year death and 1-year death or
dependence. Infratentorial location did not show a statistically
significant association. However, the direction and magnitude
of the nonsignificant association were similar to deep ICH.
Discussion
This prospective, community-based cohort study has
shown that some CT biomarkers of SVD, both individu-
ally and as part of the CT SVD score, are independently
associated with 1-year death and death or dependence fol-
lowing first-ever SVD-ICH.
In line with previous studies, we found that increas-
ing age and decreasing admission GCS score, as well as
features of the acute ICH, such as increasing ICH volume
and the presence of intraventricular hemorrhage, were
independently associated with death and functional out-
come at 1 year after SVD-ICH.3 The associations of other
variables—such as sex, pre-ICH anticoagulant drug use,
and ICH location—with long-term outcome after ICH
have varied between studies.3
Baseline SVD markers on both CT and magnetic
resonance imaging (MRI) of the brain are associated with
worse prognosis after stroke, individually and when com-
bined as composite scores.11,12,19 The association between
SVD imaging biomarkers and poor functional outcome
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was strongest in those presenting with lacunar stroke, a
stroke subtype caused by SVD.19
We found that severe WMLs were associated with
1-year death or dependence after adjusting for other
known predictors of long-term outcome after ICH. Severe
WMLs approached but did not achieve a statistically sig-
nificant association with death, which was probably due to
a lack of power. These findings concur with previous data
showing an association between WMLs and short and
medium-term outcome after ICH. In a recent meta-
analysis of 9 studies and 4,948 participants with ICH,
WMLs on CT or MRI of the brain were associated with
both death (OR = 1.59, 95% CI = 1.21–2.08) and worse
functional outcome (OR = 1.40, 95% CI = 1.17–1.68)
during short and medium-term follow-up (28–90 days).13
However, there was significant heterogeneity between the
included studies, with several potential confounders, such
as study design and mean ICH volume.
Two studies have shown an association between
cerebral atrophy and 90-day death or major dependence
following ICH.14,15 However, both had selection biases,
because participants with severe ICH or pre-ICH depen-
dence were excluded. We show similar findings, with
independent associations between severe atrophy and both
1-year death and death or dependence. In contrast, cere-
bral atrophy was associated with a good 90-day functional
outcome in one small study.16 This conflicting result
probably relates to differences in participant selection, as
this study included a very specific subgroup of participants
with moderate volume basal ganglia ICH.16 In our study,
we included all patients with ICH regardless of pre-ICH
dependence, ICH location, and ICH severity.
Few studies have assessed the prognostic value of
lacunes after ICH. One study did not identify a statisti-
cally significant association between lacunes and outcome
after ICH.14 Similarly, we did not find an association
between lacunes and 1-year death and death or
dependence.
In separate models, we showed that the composite
CT SVD score was associated with both death and death
or dependence at 1 year. Composite SVD burden scores
have shown prognostic value over individual SVD bio-
markers in ischemic stroke.11,17,18 Composite MRI SVD
scores were associated with poor functional outcome at
discharge21 and 90 days20 after ICH in 2 recent studies.
However, both studies were small and had selection biases,
and the analyses were at risk of overfitting. To the best of
our knowledge, this is the first study showing an associa-
tion between the CT SVD score and longer-term clinically
relevant outcomes after ICH.
The mechanisms underlying the association of
WMLs and atrophy with outcome after ICH remain
unclear. The severity of these biomarkers may indicate the
frailty of the underlying brain, which could influence sus-
ceptibility to and recovery from ICH. Potential mecha-
nisms include reduced connectivity and neural plasticity
in WMLs, which can influence recovery.40,41 WMLs and
atrophy are associated with poststroke cognitive impair-
ment in the elderly,7,8,42,43 which in turn is a predictor
for outcome after stroke.44
This study has strengths. We used data from a con-
temporary, prospective, community-based ICH cohort,
which used multiple overlapping sources of case ascertain-
ment and had low levels of missing data, to reduce selec-
tion bias and increase generalizability. We restricted our
analyses to patients with first-ever SVD-ICH to provide a
standard inception point. We minimized information bias
for CT risk factor assessment by standardizing imaging
format and rating of the diagnostic noncontrast brain CT
using a standardized pro forma masked to clinical and out-
come data. Patients were followed up using multiple
sources of data. To minimize overfitting, we prespecified
the risk factors for the logistic regression models based on
evidence from the literature,3,4 prespecified the outcomes,
and restricted the number of risk factors to ensure there
were at least 10 outcomes per variable in all models. We
performed sensitivity analyses, the results of which did not
change our conclusions.
Our study has limitations. The 1-year modified
Rankin Scale score was rated using a postal questionnaire
sent to the patients’ primary care practitioners. The pri-
mary care practitioners may not have specifically assessed
the patient for this purpose, which could influence the
accuracy of these data.45 However, mental incapacity is
common among survivors of ICH; therefore, the modified
Rankin Scale may be difficult to obtain from the patient
directly, and using carers to assess functional abilities for
some patients could result in bias.46 Also, patients’ percep-
tion of disability can vary according to their demo-
graphics, resulting in discrepancies in modified Rankin
Scale scores compared with assessment by trained profes-
sionals.47 Mass effect from the acute ICH, acute hydro-
cephalus, and perihematomal edema on CT may impair
the assessment of SVD biomarkers. We tried to minimize
this effect by assessing WMLs and atrophy in the cerebral
hemisphere contralateral to the acute ICH (see Fig 1).
MRI has better accuracy than CT for demonstrating SVD
biomarkers,26 and would provide a more comprehensive
imaging SVD assessment. However, CT is the most fre-
quent type of brain imaging to diagnose ICH and has few
contraindications, unlike MRI. Our approach reflects clin-
ical practice in many parts of the world and makes the
results more generalizable. Finally, do not attempt resusci-
tation orders and withdrawal of active care are known
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predictors of death in those with ICH considered to have
a poor prognosis ICH,36–38 whereas physical therapy and
rehabilitation may improve functional outcome after
ICH.39 Although there were no local guidelines for these
interventions during the study period, their use may have
been influenced by some of the variables included in the
models, such as age, admission GCS score, and brain CT
features.36–38 Therefore, although the measured outcomes
may result from direct effects of the risk factors, we cannot
exclude the differential effects of do not attempt resuscita-
tion orders, withdrawal of active care, and the provision of
rehabilitation according to CT SVD biomarkers.36,48,49
However, severe atrophy and CT SVD score ≥ 1 remained
independently associated with 1-year death and functional
outcomes in sensitivity analyses restricted to those who
survived at least 30 days.
In conclusion, SVD biomarkers on the diagnostic
brain CT are associated with 1-year death and dependence
after ICH, independent of age, features of the acute ICH,
and other known prognostic factors. Future studies should
assess whether the associations of CT SVD biomarkers
with outcome after ICH can be reproduced in larger
cohorts and participants of different ethnicities.
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